CATALAYER NEWS

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi

Source: Investing.com · 2026-10-23

Full article text is available in the Catalayer news terminal.

MORE FROM INVESTING.COM
AMTD Digital reports 23% asset growth, acquires New York hotel
2026-10-23
River City Bank reports Q3 net income of $30.6 million
2026-10-23
BuzzFeed chief legal officer David Arroyo resigns, effective November 6
2026-10-23
Novagold updates proxy statement with supplemental disclosures ahead of shareholder vote
2026-10-23
Hyperliquid Strategies increases buyback program to $100 million
2026-10-23
RELATED ON CATALAYER
Mentioned Tickers
$ABBV · AbbVie
Related Topics
Biotech & FDA News
RELATED MARKETS
Prediction Markets
Xi Jinping out before 2027?3%Will Gavin Newsom win the 2028 Democratic presidential nomination?15%Will Alexandria Ocasio-Cortez win the 2028 Democratic presidential nomination?18%
Open Catalayer terminal for live tracking →